Disposables: A Solution for Efficient Biopharmaceutical Production - Disposables are growing in popularity because of the large numbers of biological drugs being developed, which require aseptic proc


Disposables: A Solution for Efficient Biopharmaceutical Production
Disposables are growing in popularity because of the large numbers of biological drugs being developed, which require aseptic processes.

BioPharm International
Volume 19, Issue 7

Biopharmaceutical companies around the world use disposable processing equipment for numerous reasons. According to Barres's 3rd Annual Report and Survey on Biopharmaceutical Manufacturing,1 they are to minimize or improve, in order of importance, cross-contamination, cleaning, time-to-start, capital investment, production cycle, and assurance of sterility. The priority varies, of course, according to a drug company's business objectives. For example, vaccine manufacturers regard cleaning and sterility as the most important reasons for adopting this processing model. Contract manufacturing organizations (CMOs) use disposable technologies because they minimize the risks of cross-contamination. Biotechnology manufacturing firms view disposables as a way to reduce capital investment.

Hélène Pora
But whatever their priority, most companies agree that disposables, also known as "single-use systems," make it easier to conduct their operations. Disposables can dramatically simplify the transfer of applications across multiple plants, because single-use systems are flexible, modular, and customizable. And if disposables already have been designed into the process elsewhere, qualification and validation are simpler. Training is easier, too, with disposables: The installation of reusable equipment is labor-intensive and costly, and their operation may vary significantly, depending on the age of individual systems. The consistency of disposable systems allows more universal operator training.

Disposables also eliminate the need for disassembly and cleaning, minimizing operator exposure to high potency formulations or biologically toxic compounds, such as new vaccines and cancer therapeutics. While operator risks associated with small molecules and synthetic drugs are significant, the hazards of working with live viruses in vaccine production are even greater.


Table 1. Comparison of the time required to perform filtration various steps in monoclonal anitbody production when using disposable filtration systems for MAb.
Disposables are growing in popularity because of the large number of biological drugs being developed and produced, all of which require aseptic processes.

The flu vaccine compliance failures of 2004 highlight the difficulties of ensuring the sterility of large-molecule drug products that can neither be heat-sterilized nor pass through a sterilizing grade filter. Disposables go a long way toward simplifying the complex task of achieving aseptic control and proving it to the FDA.


With global revenues for contract research and manufacturing projected to reach $168 billion by 2009, efforts to minimize cross-contamination risks have become a top concern for CMOs and contract research organizations.2 Many of these companies consider disposable technologies to be a key part of the firm's strategy to expand product lines without compromising safety. The ability to use filters, chromatography membranes, tubing, bags, and connection devices once, and then throw them away, means that there is no chance for batch-to-batch, or even more important, product-to-product, contamination.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here